Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.

NCT Number	NCT06389513
Lead Sponsor	CanSino Biologics Inc.
Conditions	Epidemic Meningitis
Enrollment	3,011 participants
Start Date	2024-06-12
Primary Completion	2026-04-10 (estimated)
Study Completion	2026-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-13